Entering text into the input field will update the search result below

Avanir skyrockets premarket on trial results

Sep. 15, 2014 9:16 AM ETAvanir Pharmaceuticals, Inc (AVNR) StockBy: Douglas W. House, SA News Editor1 Comment
  • Avanir Pharmaceuticals (NASDAQ:AVNR) explodes 46% premarket on massive volume in response to its announcement of positive results from its Phase 2 trial evaluating AVP-923 for the treatment of agitation in patients with Alzheimer's disease. AVP-923 achieved the primary endpoint of a statistically significant reduction in agitation versus placebo (p=0.00008).
  • There are no FDA-approved drugs for this indication.
  • Avanir will present the study results at the American Neurological Association's Annual Meeting in Baltimore, MD, October 12-14, 2014.

Recommended For You

Related Stocks

SymbolLast Price% Chg
AVNR--
Avanir Pharmaceuticals, Inc